Skip to main content

Advertisement

SpringerLink
Log in

Update on Immune Checkpoint Inhibitor-Associated Uveitis

  • Published:
Current Ophthalmology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In this article, we review the current updates on immune checkpoint inhibitors (ICPIs) and the management of ICPI-associated uveitis.

Recent Findings

ICPI-associated uveitis usually presents within 6 months of ICPI initiation. The spectrum of vision loss ranges from mild to severe, and may be as poor as light perception. In recent years, various societies have published guidelines with updated management recommendations for ICPI-associated uveitis. Steroids and cessation of ICPI administration remain the mainstays of treatment. The visual prognosis is generally good with appropriate treatment. Recalcitrant inflammation or secondary effects from steroid therapy may contribute to vision loss.

Summary

ICPI-associated uveitis may be vision-threatening in some patients, but often exhibits a significant response to steroid therapy. Treatment of ICPI-associated uveitis requires a multidisciplinary approach. Patients who are suspected to have ICPI-associated uveitis should be referred to a uveitis specialist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. https://doi.org/10.1038/nrc3239.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30:660–9. https://doi.org/10.1038/s41422-020-0343-4.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921–5. https://doi.org/10.1016/j.cub.2020.06.081.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bristol-Myers Squibb Company. Yervoy (Ipilimumab) Injection [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Company; 2017.

    Google Scholar 

  6. AstraZeneca Pharmaceuticals LP. Imjudo (Tremelimumab-actl) Injection, for Intravenous Use [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022.

  7. Bristol-Myers Squibb Company. Opdivo (Nivolumab) Injection [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Company; 2017.

    Google Scholar 

  8. Merck & Company Inc. Keytruda (Pembrolizumab) for Injection [Prescribing Information]. Whitehosue Station, NJ: Merck & Co, Inc; 2017.

  9. Genentech Inc. Tecentriz (Atezolizumab) Injection [Prescribing Information]. South San Francisco, CA: Genentech, Inc; 2017.

  10. EMD Serono Inc. Bavencio (Avelumab) Injection, for Intravenous Use [Prescribing Information]. Rockland, MD: EMD Serono, Inc and Pfizer, Inc; 2017.

  11. AstraZeneca Pharmaceuticals LP. Imfinzi (Durvalumab) Injection, for Intravenous Use [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.

  12. Regeneron. Libtayo (Cemiplimab) Injection [Prescribing Information]. Tarrytown, NY: Regeneron Pharmaceuticals Inc; 2020.

  13. Bristol-Myers Squibb Company. Opdualag (Nivolumab and Relatlimab-rmbw) Injection, for Intravenous Use [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

    Google Scholar 

  14. Wessely A, Steeb T, Erdmann M, Heinzerling L, Vera J, Schlaak M, Berking C, Heppt MV. The Role of Immune Checkpoint Blockade in Uveal Melanoma. Int J Mol Sci. 2020;21(3):879. https://doi.org/10.3390/ijms21030879.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98–106. https://doi.org/10.1097/COC.0000000000000239.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol. 2018;28(8):86. https://doi.org/10.3389/fonc.2018.00086.

    Article  Google Scholar 

  17. Sharpe A, Pauken K. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153–67. https://doi.org/10.1038/nri.2017.108.

    Article  CAS  PubMed  Google Scholar 

  18. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P, Zeng Y, Chen H. The promising immune checkpoint LAG-3 from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5–6):176–89. https://doi.org/10.18632/genesandcancer.180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Graydon CG, Mohideen S, Fowke KR. LAG3’s Enigmatic Mechanism of Action. Front Immunol. 2021;11:615317. https://doi.org/10.3389/fimmu.2020.615317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13:392. https://doi.org/10.1038/s41467-022-27960-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19:254–67.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol. 2017;8(8):49. https://doi.org/10.3389/fphar.2017.00049.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford). 2019;58(Suppl 7):vii7–16. https://doi.org/10.1093/rheumatology/kez418.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, MalekiVareki S, Fernandes R. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134. https://doi.org/10.1016/j.ctrv.2020.102134.

    Article  CAS  PubMed  Google Scholar 

  26. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. •• Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina. 2018;38(6):1063–78. https://doi.org/10.1097/IAE.0000000000002181. A comprehensive review of checkpoint inhibitor mechanisms of action and associated ocular immune-related adverse events.

    Article  CAS  PubMed  Google Scholar 

  28. Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol. 2021;105:1263–71.

    Article  PubMed  Google Scholar 

  29. Medawar P. Immunity to homologous grafted skin. III. the fate of skin homografts transplanted to the brain to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29:58–69.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol. 2003;74(2):179–85. https://doi.org/10.1189/jlb.1102574.

    Article  CAS  PubMed  Google Scholar 

  31. Taylor AW, Kaplan HJ. Ocular immune privilege in the year 2010: ocular immune privilege and uveitis. Ocul Immunol Inflamm. 2010;18(6):488–92. https://doi.org/10.3109/09273948.2010.525730.PMID:21091058;PMCID:PMC3329254.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Young L, Finnigan S, Streicher H, Chen HX, Murray J, Sen HN, Sharon E. Ocular adverse events in PD-1 and PD-L1 inhibitors. J Immunother Cancer. 2021;9(7):e002119. https://doi.org/10.1136/jitc-2020-002119.

    Article  PubMed  PubMed Central  Google Scholar 

  33. •• Chaudot F, Sève P, Rousseau A, et al. Ocular Inflammation Induced by Immune Checkpoint Inhibitors. J Clin Med. 2022;11(17):4993. https://doi.org/10.3390/jcm11174993. A case series of 22 cases of CI-associated uveitis, as well as a comprehensive literature review of reported cases of CI-associated uveitis.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. • Sun MM, Levinson RD, Filipowicz ADO, et al. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocul Immunol Inflamm. 2020;28(2):217–27. https://doi.org/10.1080/09273948.2019.1577978. A case series adding 14 cases of CI-associated uveitis, with detailed clinical presentation, treatment course, and outcomes. 

    Article  CAS  PubMed  Google Scholar 

  35. •• Dow ER, Yung M, Tsui E. Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes. Ocul Immunol Inflamm. 2021;29(1):203–11. https://doi.org/10.1080/09273948.2020.1781902. A comprehensive review of the characteristics and treatment of CI-associated uveitis.

    Article  CAS  PubMed  Google Scholar 

  36. Sun MM, Kelly SP, Mylavarapu BAL, Holland GN, Coleman AL, Yu F, Hsu MS, Lum F, Gordon LK. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology. 2021;128:910–9.

    Article  PubMed  Google Scholar 

  37. Alba-Linero C, Alba E. Ocular side effects of checkpoint inhibitors. Surv Ophthalmol. 2021;66:951–9.

    Article  PubMed  Google Scholar 

  38. Vrabic N, Fakin A, Mekjavic PJ, Janzic U, Vrankar M, Valentincic NV. Various Clinical Presentations of Uveitis Associated with Durvalumab Treatment. Radiol Oncol. 2022;56(2):129–37. https://doi.org/10.2478/raon-2022-0007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Dow ER, Hou K, Ransome S, Abbassi S, Tsui E. Posterior Uveitis Associated with Cemiplimab. Ocul Immunol Inflamm. 2022;30(5):1211–3. https://doi.org/10.1080/09273948.2021.1872649.

    Article  CAS  PubMed  Google Scholar 

  40. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. NEJM. 2018;378:158–68. https://doi.org/10.1056/NEJMra1703481.

    Article  CAS  PubMed  Google Scholar 

  41. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–53. https://doi.org/10.1001/jamaoncol.2016.1051.

    Article  PubMed  Google Scholar 

  42. Bomze D, Meirson T, Ali OH, Goldman A, Flatz L, Habot-Wilner Z. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. Ocul Immunol Inflamm. 2022;30:191–7.

    Article  CAS  PubMed  Google Scholar 

  43. Cunningham ET, Moorthy RS, Zierhut M. Immune Checkpoint Inhibitor-Induced Uveitis. Ocul Immunol Inflamm. 2020;28(6):847–9. https://doi.org/10.1080/09273948.2020.1801286.

    Article  PubMed  Google Scholar 

  44. Minami K, Egawa M, Kajita K, Murao F, Mitamura Y. A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy. Case Rep Ophthalmol. 2021;12(3):952–60. https://doi.org/10.1159/000520416.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A. Checkpoint inhibitor-induced uveitis: a case series. Graefe’s Archive for Clin Exp Ophthalmol. 2017;256(1):187–91. https://doi.org/10.1007/s00417-017-3835-2.

    Article  Google Scholar 

  46. Andrade RA, Moll-Udina A, Martin R, Cilveti E, Subirà O, Disfetano L, García-Arumí J. Retinal Vasculitis Secondary to Durvalumab. Case Rep Ophthalmol. 2020;11:161–6. https://doi.org/10.1159/000507609.

    Article  Google Scholar 

  47. Thomas M, Armenti ST, Ayres MB, Demirci H. Uveal Effusion After Immune Checkpoint Inhibitor Therapy. JAMA Ophthalmology. 2018;136(5):553. https://doi.org/10.1001/jamaophthalmol.2018.0920.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Emens LA, Davis SL, Oliver SCN, Lieu CH, Reddy A, Solomon S, …, Ferrara D. Association of cancer immunotherapy with acute macular neuroretinopathy and diffuse retinal venulitis. JAMA Ophthalmol. 2018. https://doi.org/10.1001/jamaophthalmol.2018.5191

  49. Ramtohul P, Freund BK. Clinical and morphological characteristics of anti-Pd-L1-associated retinopathy. Ophthalmol Retina. 2019. https://doi.org/10.1016/j.oret.2019.11.006

  50. Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma. JAMA Ophthalmology. 2015;133(8):965. https://doi.org/10.1001/jamaophthalmol.2015.1128.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Tsui E, Madu A, Belinsky I, Yannuzzi LA, Freund KB, Modi YS. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated with Ciliochoroidal Effusion and Exudative Retinal Detachment. JAMA Ophthalmol. 2017;135:1455–7.

    Article  PubMed  Google Scholar 

  52. O’Bryhim BE, Sychev Y, Rao PK. Bilateral choroidal detachments secondary to ipilimumab and pembrolizumab use. Retin Cases Brief Rep. 2021;15(3):230–3. https://doi.org/10.1097/ICB.0000000000000785.

    Article  PubMed  Google Scholar 

  53. Acaba-Berrocal LA, Lucio-Alvarez JA, Mashayekhi A, Ho AC, Dunn JP, Shields CL. Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment. JAMA Ophthalmol. 2018;136(10):1205–7. https://doi.org/10.1001/jamaophthalmol.2018.1851.

    Article  PubMed  Google Scholar 

  54. Lavezzo MM, Sakata VM, Morita C, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis. 2016;11(1):29. https://doi.org/10.1186/s13023-016-0412-4.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Godse R, Mcgettigan S, Schuchter LM, Ellebrecht CT, Chu EY. Vogt–Koyanagi–Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy. Clin Exp Dermatol. 2021;46(6):1111–2. https://doi.org/10.1111/ced.14640.

    Article  CAS  PubMed  Google Scholar 

  56. Shindo Y, Inoko H, et al. HLA-DRB1 typing of Vogt-Koyanagi-Harada’s disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994;78(3):223–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Kikuchi R, Kawagoe T, Hotta K. Vogt–Koyanagi–Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol. 2020;20:252. https://doi.org/10.1186/s12886-020-01519-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol. 2016;44(8):975–6. https://doi.org/10.1111/1346-8138.13612.

    Article  PubMed  Google Scholar 

  59. Fujimura T, Kambayashi Y, Tanita K, et al. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol. 2018;45(6):735–7. https://doi.org/10.1111/1346-8138.14273.

    Article  CAS  PubMed  Google Scholar 

  60. Tan AX, Ang A, Campbell WG, Fabinyi DC. Bilateral ipilimumab-induced posterior uveitis following treatment for metastatic choroidal melanoma. Clin Experiment Ophthalmol. 2018. https://doi.org/10.1111/ceo.13197.

    Article  PubMed  Google Scholar 

  61. Fierz F, Meier F, Chaloupka K, Böni C. Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma – Case Series and Review. Klin Monatsbl Augenheilkd. 2016;233(04):540–4. https://doi.org/10.1055/s-0042-102668.

    Article  CAS  PubMed  Google Scholar 

  62. Kanavati S, Ottensmeier C, Foria V, Krishnan R. Bilateral metastatic cutaneous melanoma to retina and vitreous after ipilimumab treated with pars plana vitrectomy and radiotherapy. Retin Cases Brief Rep. 2018;12(3):184–7. https://doi.org/10.1097/ICB.0000000000000477.

    Article  PubMed  Google Scholar 

  63. Hoogewoud F, Butori P, Blanche P, Brézin AP. Cancer-associated retinopathy preceding the diagnosis of cancer. BMC Ophthalmol. 2018;18(1):285. https://doi.org/10.1186/s12886-018-0948-2.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol. 2001;21:173–87.

    Article  CAS  PubMed  Google Scholar 

  65. Sandhu HS, Kolomeyer AM, Lau MK, Shields CL, Schuchter LM, Nichols CW, Aleman TS. Acute exudative paraneoplastic polymorphous vitelliform maculopathy during vemurafenib and pembrolizumab treatment for metastatic melanoma. Retin Cases Brief Rep. 2019;13(2):103–7. https://doi.org/10.1097/ICB.0000000000000604.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Lambert I, Fasolino G, Awada G, et al. Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report. BMC Ophthalmol. 2021;21:250. https://doi.org/10.1186/s12886-021-02011-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Aronow ME, Adamus G, Abu-Asab M, Wang Y, Chan C-C, Zakov ZN, Singh AD. Paraneoplastic Vitelliform Retinopathy: Clinicopathologic Correlation and Review of the Literature. Surv Ophthalmol. 2012;57(6):558–64. https://doi.org/10.1016/j.survophthal.2012.02.

    Article  PubMed  PubMed Central  Google Scholar 

  68. • Venkat AG, Arepalli S, Sharma S, Karthik N, Lowder C, Ehlers JP, …, Srivastava S. Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. British J Ophthalmolbjophthalmol. 2019. https://doi.org/10.1136/bjophthalmol-2019-314403. A case series and literature review detailing the role of local therapy for IC-related uveitis.

  69. Tsui E, Gonzales JA. Retinal Vasculitis Associated with Ipilimumab. Ocul Immunol Inflamm. 2020;28(6):868–70. https://doi.org/10.1080/09273948.2019.1610460.

    Article  CAS  PubMed  Google Scholar 

  70. Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer. JCO. 2018;36:2872–8.

    Article  CAS  Google Scholar 

  71. Wilson MA, Guld K, Galetta S, et al. Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunotherapy Cancer. 2016;4:66. https://doi.org/10.1186/s40425-016-0170-9

  72. Yoshida M, Kunikata H, Nakazawa T. Intraocular Concentrations of Cytokines and Chemokines in a Unique Case of Nivolumab-Induced Uveitis. Ocul Immunol Inflamm. 2020;28(6):850–3. https://doi.org/10.1080/09273948.2019.1582785.

    Article  CAS  PubMed  Google Scholar 

  73. Common Terminology Criteria for Adverse Events (CTCAE). Published online 2017:155. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60.

  74. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–16. https://doi.org/10.1016/j.ajo.2005.03.057

  75. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073–126. https://doi.org/10.1200/JCO.21.01440.

    Article  CAS  PubMed  Google Scholar 

  76. Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Nat Comprehensive Cancer Network. 2019;17(3):255–89. https://doi.org/10.6004/jnccn.2019.0013.

    Article  CAS  Google Scholar 

  77. Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, …, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J ImmunoTherapy of Cancer 2021;9(6)e002435. https://doi.org/10.1136/jitc-2021-002435

  78. Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report. Can J Ophthalmol. 2016;51(1):e4–6. https://doi.org/10.1016/j.jcjo.2015.09.008.

    Article  PubMed  Google Scholar 

  79. Lee JC, Al-Humimat G, Kooner KS. Acute Bilateral Uveitis, Hypotony, and Cataracts Associated with Ipilimumab and Nivolumab Therapy: Optical Coherence Tomography Angiography Findings. Case Rep Ophthalmol. 2020;11(3):606–11. https://doi.org/10.1159/000509629.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Parikh RA, Chaon BC, Berkenstock MK. Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series. Ocular Immunol Inflammation. 2020;1–6.

  81. Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee J-M, …, Sen HN. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocular ImmunolInflam. 2019;28:(6)854–859. https://doi.org/10.1080/09273948.2019.1583347

  82. Deitch-Harel I, Raskin E, Habot-Wilner Z, Friling R, Amer R, Kramer M. Uveitis Induced by Biological Agents Used in Cancer Therapy. Ocul Immunol Inflamm. 2021;29:1370–4.

    Article  CAS  PubMed  Google Scholar 

  83. Bitton K, Michot J-M, Barreau E, Lambotte O, Haigh O, Marabelle A, …, Rousseau A. Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy. Am J Ophthalmol. 2019. https://doi.org/10.1016/j.ajo.2019.02.012

  84. Miyamoto R, Nakashizuka H, Tanaka K, et al. Bilateral multiple serous retinal detachments after treatment with nivolumab: a case report. BMC Ophthalmol. 2020;20:221. https://doi.org/10.1186/s12886-020-01495-w.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Suwa S, Tomita R, Kataoka K, Ueno S. Development of Vogt–Koyanagi–Harada disease-like uveitis during treatment by anti-programmed death ligand-1 antibody for non-small cell lung c: a case report. Ocular Immunol Inflamm. 2021;1–5. https://doi.org/10.1080/09273948.2021.1884889

  86. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–12. https://doi.org/10.1016/S1470-2045(14)70189-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32. https://doi.org/10.1056/NEJMoa1503093.

    Article  CAS  PubMed  Google Scholar 

  88. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18. https://doi.org/10.1016/S1470-2045(15)00083-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA

    Christian Kim, Samantha Paul & Jose Echegaray

Authors
  1. Christian Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samantha Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose Echegaray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Kim.

Ethics declarations

Conflict of Interest

Christian Kim, Samantha Paul, and Jose Echegaray declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, C., Paul, S. & Echegaray, J. Update on Immune Checkpoint Inhibitor-Associated Uveitis. Curr Ophthalmol Rep 11, 57–67 (2023). https://doi.org/10.1007/s40135-023-00312-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40135-023-00312-z

Keywords

Search

Navigation